Antikörpervermittelte Neuropathien

Lernziele

Kenntnis von:

• klinischem und neurophysiologischem Spektrum,

• differenzialdiagnostische und -therapeutische Rolle der neurophysiologischen Diagnostik,

• differenzialdiagnostische und -therapeutische Rolle des Nachweises von spezifischen Autoantikörpern

bei Patienten mit antikörpervermittelten Neuropathien.

• Literatur

• 1 Uncini A, Notturno F, Capasso M. Natura non facit saltus in anti-ganglioside antibody-mediated neuropathies. Muscle Nerve 2013; 48: 484-487
• 2 Busch V, Schulte-Mattler WJ. Differentiation between uniform and non-uniform motor nerve conduction slowing. Clin Neurophysiol 2010; 121: 890-894
• 3 Pöschl P, Schulte-Mattler W. Der neurophysiologische Nachweis peripherer Myelinschäden. Klin Neurophysiol 2011; 42: 239-246
• 4 Thaisetthawatkul P, Logigian EL, Herrmann DN. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2002; 205: 59-63
• 5 Schulte-Mattler W. Conduction Velocity Distribution. In: Kimura J, editor. Neurophysiology of Peripheral Nerve Diseases. Handbook of Clinical Neurophysiology. Amsterdam: Elsevier; 2006: 405-419
• 6 Kornhuber ME, Bischoff C, Mentrup H et al. Multiple A waves in Guillain-Barré syndrome. Muscle Nerve 1999; 22: 394-399
• 7 Yuki N, Uncini A. Acute and chronic ataxic neuropathies with disialosyl antibodies: A continuous clinical spectrum and a common pathophysiological mechanism. Muscle Nerve 2014; 49: 629-635
• 8 Chavada G, Willison HJ. Autoantibodies in immune-mediated neuropathies. Current Opinion in Neurology 2012; 25: 550-555
• 9 Ng JKM, Malotka J, Kawakami N et al. Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 2012; 79: 2241-2248
• 10 Willison HJ, Veitch J, Paterson G et al. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatr 1993; 56: 204-206
• 11 Sekiguchi Y, Uncini A, Yuki N et al. Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: A Japanese-Italian collaborative study. Journal of Neurology, Neurosurgery & Psychiatry 2011; 83: 23-28
• 12 Shahrizaila N, Kokubun N, Sawai S et al. Antibodies to single glycolipids and glycolipid complexes in Guillain-Barré syndrome subtypes. Neurology 2014; 83: 118-124
• 13 Capasso M, Notturno F, Manzoli C et al. Involvement of sensory fibres in axonal subtypes of Guillain-Barré syndrome. Journal of Neurology, Neurosurgery & Psychiatry 2011; 82: 664-670
• 14 Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go. J Peripher Nerv Syst 2014; 19: 2-13
• 15 Saperstein DS, Katz JS, Amato AA et al. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001; 24: 311-324
• 16 Larue S, Bombelli F, Viala K et al. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. European Journal of Neurology 2011; 18: 899-905
• 17 Stork ACJ, van der Pol W, Franssen H et al. Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature. J Neurol 2014; 261: 1398-1404
• 18 Dispenzieri A. POEMS syndrome: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89: 213-223
• 19 Nasu S, Misawa S, Sekiguchi Y et al. Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. Journal of Neurology, Neurosurgery & Psychiatry 2012; 83: 476-479
• 20 Koike H, Tanaka F, Sobue G. Paraneoplastic neuropathy. Current Opinion in Neurology 2011; 24: 504-510
• 21 Caudie C, Quittard Pinon A, Bouhour F et al. Comparison of commercial tests for detecting multiple anti-ganglioside autoantibodies in patients with well-characterized immune-mediated peripheral neuropathies. Clin Lab 2013; 59: 1277-1287
• 22 Moriguchi K, Miyamoto K, Takada K et al. Four cases of anti-ganglioside antibody-positive neuralgic amyotrophy with good response to intravenous immunoglobulin infusion therapy. Journal of Neuroimmunology 2011; 238: 107-109
• 23 Kuwabara S, Yuki N. Axonal Guillain-Barré syndrome: concepts and controversies. The Lancet Neurology 2013; 12: 1180-1188
• 24 Querol L, Nogales-Gadea G, Rojas-Garcia R et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 2014; 82: 879-886
• 25 Willison HJ. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001; 124: 1968-1277
• 26 Löscher WN, Woertz A, Wallnöfer M et al. Successful treatment of CANOMAD with IVIg and rituximab. J Neurol 2013; 260: 1168-1170
• 27 Antoine J, Honnorat J, Camdessanche J et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001; 49: 214-221